|
|
 Previous Article | Table of Contents | Next Article 
Cytomegalovirus infection after autologous bone marrow transplantation with
comparison to infection after allogeneic bone marrow transplantation
JR Wingard, DY Chen, WH Burns, DJ Fuller, HG Braine, AM Yeager, H Kaiser, PJ Burke, ML Graham and GW Santos
Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Cytomegalovirus (CMV) infection was detected in 65 of 143 (45%) autologous
bone marrow transplant (BMT) patients. CMV pneumonitis occurred in only 2%
of the patients and CMV retinitis occurred in none. Infection occurred in
half of the 40 initially seronegative patients and 47% of the 94 initially
seropositive patients. Among initially seropositive patients, platelet
recovery was slower in infected patients than in those not infected (97 v
35 days median, P = .003), and neutrophil recovery was slightly delayed in
infected patients (31 days v 24 days, P = .02). Although the incidence of
CMV infection was comparable in autologous and allogeneic BMT patients, CMV
pneumonitis was less frequent in autologous BMT patients (2% v 12%, P less
than .001). The risk for CMV pneumonitis in autologous BMT patients was
comparable with that in allogeneic BMT patients without graft-v-host
disease (GVHD) (2% v 6%), but significantly lower than the risk in
allogeneic BMT patients with GVHD (2% v 23%, P less than .001).
Volume 71,
Issue 5,
pp. 1432-1437,
05/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. M. Marty, J. Bryar, S. K. Browne, T. Schwarzberg, V. T. Ho, I. V. Bassett, J. Koreth, E. P. Alyea, R. J. Soiffer, C. S. Cutler, et al.
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
Blood,
July 15, 2007;
110(2):
490 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Roback, M. S. Hossain, L. Lezhava, J. W. Gorechlad, S. A. Alexander, D. L. Jaye, S. Mittelstaedt, S. Talib, J. E. Hearst, C. D. Hillyer, et al.
Allogeneic T Cells Treated with Amotosalen Prevent Lethal Cytomegalovirus Disease without Producing Graft-versus-Host Disease Following Bone Marrow Transplantation
J. Immunol.,
December 1, 2003;
171(11):
6023 - 6031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Goldberg, A. L. Pecora, R. S. Alter, M. S. Kroll, S. D. Rowley, S. E. Waintraub, K. Imrit, and R. A. Preti
Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab
Blood,
February 15, 2002;
99(4):
1486 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Podlech, R. Holtappels, M.-F. Pahl-Seibert, H.-P. Steffens, and M. J. Reddehase
Murine Model of Interstitial Cytomegalovirus Pneumonia in Syngeneic Bone Marrow Transplantation: Persistence of Protective Pulmonary CD8-T-Cell Infiltrates after Clearance of Acute Infection
J. Virol.,
August 15, 2000;
74(16):
7496 - 7507.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. P. Alessandrino, M. Varettoni, A. A. Colombo, D. Caldera, P. Bernasconi, L. Malcovati;, L. A. Holmberg, and W. I. Bensinger
High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
Blood,
June 15, 2000;
95(12):
4016 - 4018.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Holmberg, M. Boeckh, H. Hooper, W. Leisenring, S. Rowley, S. Heimfeld, O. Press, D. G. Maloney, P. McSweeney, L. Corey, et al.
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation
Blood,
December 15, 1999;
94(12):
4029 - 4035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Iwata, J. Vieira, M. Byrne, H. Horton, and B. Torok-Storb
Interleukin-1 (IL-1) Inhibits Growth of Cytomegalovirus in Human Marrow Stromal Cells: Inhibition Is Reversed Upon Removal of IL-1
Blood,
July 15, 1999;
94(2):
572 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alterio de Goss, R. Holtappels, H.-P. Steffens, J. Podlech, P. Angele, L. Dreher, D. Thomas, and M. J. Reddehase
Control of Cytomegalovirus in Bone Marrow Transplantation Chimeras Lacking the Prevailing Antigen-Presenting Molecule in Recipient Tissues Rests Primarily on Recipient-Derived CD8 T Cells
J. Virol.,
October 1, 1998;
72(10):
7733 - 7744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Torok-Storb, M. Boeckh, C. Hoy, W. Leisenring, D. Myerson, and T. Gooley
Association of Specific Cytomegalovirus Genotypes With Death From Myelosuppression After Marrow Transplantation
Blood,
September 1, 1997;
90(5):
2097 - 2102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Mori, K. Ando, K. Tanaka, Y. Ikeda, and Y. Koga
Fas-Mediated Apoptosis of the Hematopoietic Progenitor Cells in Mice Infected With Murine Cytomegalovirus
Blood,
May 15, 1997;
89(10):
3565 - 3573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage
Bone Marrow Transplantation
N. Engl. J. Med.,
March 24, 1994;
330(12):
827 - 838.
[Full Text]
|
|
|
|
|
